Diluting topical finasteride with coconut oil is discussed, with a suggestion to use topical minoxidil for a combined treatment. OP plans to try the minoxidil combination.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
OP asked if Alfatradiol 0.1% can maintain hair after a transplant. Responses suggest using stronger treatments like finasteride or micro-dosing oral finasteride instead.
A poem humorously suggests hope for a new hair loss treatment, PP405, while users debate the effectiveness and side effects of current treatments like Finasteride. Concerns are raised about Finasteride's side effects, especially for young users, and skepticism about new treatments is expressed.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
A hair restoration case involved injecting four different doses of Verteporfin into the mid scalp and using Scalp MicroPigmentation (SMP) around the extraction areas. Photos were taken and an update will be shared soon.
A 32-year-old man from Vietnam, at Norwood 7 hair loss, is using Minoxidil, Finasteride, rosemary oil, NMN, and CoQ10 to regrow hair. Despite minor improvements, alternatives like hair systems or accepting baldness are suggested due to advanced hair loss.
The user is experimenting with taking 1-1.5ml of pure castor oil orally daily as an alternative to minoxidil for hair growth. They aim to find a safer option that promotes overall body and head hair growth without the side effects of minoxidil.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
Hair cloning and new treatments like ET-02, Veradermics (vdphl01), and wound-induced hair neogenesis show promise but are not yet widely available. Current effective treatments include minoxidil, finasteride, and dutasteride, with early intervention being crucial for better outcomes.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
A 28-year-old is assessing their hair loss on the Norwood scale, considering adding topical minoxidil and dermastamping to their current regimen of oral finasteride and minoxidil. They feel their hair loss is worsening and seek opinions on their condition.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
The user has experienced hair regrowth after switching from topical to oral Minoxidil and starting Finasteride. Other users confirm the regrowth and suggest additional treatments like microneedling and Nizoral shampoo.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
The user has been using kx826 for 10 months and topical minoxidil for 2 years, reporting slow but undeniable progress in hair regrowth. They experienced side effects from finasteride and do not use it.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.
A 28-year-old male using Tugain 10 minoxidil, Finpecia 1mg finasteride, Cipla Ketoconazole shampoo, and dermarolling 0.5mm weekly for 3-4 months is seeing some hair regrowth. Encouragement is given to continue the regimen.
Chronic Telogen Effluvium can be managed by avoiding inflammatory foods, exercising, staying hydrated, and using supplements like krill oil, saw palmetto, or licorice root. Minoxidil is discouraged due to its cost and potential for worsening hair loss, while castor oil is recommended to strengthen hair roots and reduce shedding.
A user is seeking advice on the efficacy and side effects of homemade topical solutions for hair loss, specifically bicalutamide, estradiol, cyproterone acetate, and spironolactone, as they cannot access RU58841 or pyrilutamide.